January 24, 2020 06:17 AM ESTUpdated 06:42 AM
R&D

Roche's check­point play­er Tecen­triq flops in an­oth­er blad­der can­cer sub­set

Natalie Grover

Reporter

Just weeks af­ter Mer­ck’s star check­point in­hibitor Keytru­da se­cured FDA ap­proval for a sub­set of blad­der can­cer pa­tients, Swiss com­peti­tor Roche’s Tecen­triq has failed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

No­var­tis, Ab­b­Vie and PhRMA se­cure 340B court win in West Vir­ginia

A service from the Financial Times